Adalimumab Targets and Neutralize Specific Proinflammatory Mediator of Immune System.


Inflammation of the pigmented vascular layer of the eye — is a medical emergency responsible for up to 20% of cases of blindness1

For patients with chronic or recurrent uveitis, whose uveitis is not controlled within 3 months of treatment with ≤10mg/day, steroid-sparing therapies have become the standard of care2.

Adalimumab approved for non-infectious uveitis fills gap3.


For Noninfectious Uveitis

Swollen Joint Count

Post Marketing Surveillance

Real world Evidences

Intermediate, Posterior and Panuveitis non-infectious Uveitis

Use, Safety and Efficacy of ZRC 3197, a biosimilar candidate of reference Adalimumab from Tertiary Pediatric Rheumatology Centre in India

Clinical Data

Percentage of Vision improvement, Flare improvement and cell Improvement in pediatric uveitis patents after 3 and 6 moth of follow up


  1. de Smet MD, Taylor SR, Bodaghi B, et al. Understanding uveitis: the impact of research on visual outcomes. Progress in Retinal and Eye Research. 2011;30:452-570 doi: 10.1016/j.preteyeres.2011.06.005.
  2. Foster CS, Kothari S, Anesi SD, et al. The Ocular Immunology and Uveitis Foundation preferred practice patterns of uveitis management. Survey of Ophthalmology. 2016;61(1):1-17
  3. Agarwal M et al. Use, Safety and Efficacy of Zrc 3197, a Biosimilar Candidate for Reference Adalimumab (Humira) from a Tertiary Pediatric Rheumatology Centre in India: Proceeding of the ACR/ARHP Annual Meeting; September 28, 2016